Astellas Venture Management — Seed & Pre-Seed VC Firm ($1.5M–$10.0M Checks)
Astellas Venture Management is a Seed, Pre-Seed venture capital firm based in Menlo Park, CA investing in Healthcare, AI / ML. The firm typically writes $1.5M–$10.0M checks and has 19 portfolio companies in our records.
- Check size
- $1.5M–$10.0M
- Portfolio
- 19 companies on record
- Partners
- 1 listed
- AUM
- $68M
- Stage
- Seed, Pre-Seed
- Sectors
- Healthcare, AI / ML
- HQ
- Menlo Park, CA
Last verified: 2026-05-04
Seed, Pre-Seed
$1.5M – $10.0M
$68M
19+ companies
1 partner
About Astellas Venture Management
Astellas Venture Management is a venture capital firm headquartered in Menlo Park, California. The firm invests in early-stage therapeutic innovation with a focus on biopharma and AI-based drug design.
Astellas Venture Management participates in seed and early stage financings. It invests in the sectors of PharmaTech, Healthcare, AI Drug Discovery, and AI/ML. Typical check sizes range from $1.5M to $10.0M. The firm has $68M in assets under management. Cold outreach is an accepted approach.
Investment Thesis
Astellas Venture Management invests in early-stage therapeutic innovation, focusing on biopharma and AI-based drug design.
How Astellas Venture Management invests
Astellas Venture Management is a vc firm based in Menlo Park, CA. The firm invests at the Seed, Pre-Seed stages, with a focus on Healthcare, AI / ML.
Astellas Venture Management typically writes checks of $1.5M–$10.0M per investment, backed by approximately $68M in assets under management.
Astellas Venture Management has backed 19 companies in our records, including Atomwise, Vector BioPharma, DeepSeq.AI.
Partners & Team
Industry Focus
Invests In
Investment Track Record
Astellas Venture Management has recorded investments in 19 companies. Its portfolio includes Atomwise in AI Drug Discovery, Avilar Therapeutics and Cleave Biosciences in biotechnology focused on degradation, Casma Therapeutics in biotechnology focused on autophagy, and Catamaran Bio in oncology immunotherapy. Additional investments include CODA Biotherapeutics in biotechnology addressing neuro and antibodies, CoMentis in biotechnology focused on neuro, DeepSeq.AI, Heartseed in regenerative cardiology, PhoreMost in oncology and immuno-oncology, and Potenza Therapeutics in oncology.
The firm has also invested in Restore Vision in biotech and ophthalmology, Serna Bio, Sidewinder Therapeutics in biotech and oncology, and Solu Therapeutics. Portfolio companies have reached stages including Series B, convertible note, and outcomes such as exit and acquisition.
Portfolio Companies (19)
Other
Atomwise
Vector BioPharma
DeepSeq.AI
Serna Bio
Solu Therapeutics
Develops therapeutics targeting soluble targets in immunology and inflammation.
PhoreMost
UK-based developer of small molecule neoantigen immuno-oncology therapies.
Somite Therapeutics
Builds cellular therapies for muscle diseases using stem cell tech.
Turn Biotechnologies
Develops mRNA-based therapies for cellular rejuvenation in age-related diseases.
CoMentis
Focuses on neurodegenerative disease therapies targeting protein misfolding.
Avilar Therapeutics
Engineers protein degradation platforms for autoimmune and inflammatory diseases.
- •Raising at Seed, Pre-Seed? You're squarely in their sweet spot.
- •Lead with your fit in Healthcare, AI / ML — the sectors they actively back.
- •Size your ask to their typical $1.5M – $10.0M check.
- •cold outreach ok
- •Address your outreach to a specific partner, such as William Watt, Ph.D., President.
- •A warm introduction beats a cold email. Get matched and request an intro.
Featured In
Browse More Investors
Fundraising resources
Frequently Asked Questions
See if Astellas Venture Management is a match for your startup
Upload your pitch deck to see how well you match with Astellas Venture Management and 10,000+ other investors.
Ask your AI assistant about this investor: connect InvestorMatch to Claude or ChatGPT
Is this your profile? Request a correction or removal